Investor Presentation for Q4 & FY 2025-26
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suraksha Diagnostic reported FY26 revenue of ₹3,136 million, up 23% YoY, with EBITDA of ₹986 million, up 16%. However, EBITDA margin declined to 31.8% from 33.8% due to aggressive expansion investments. PAT grew only 1.4% to ₹314 million as finance costs rose sharply (₹126 million vs ₹84 million) and depreciation increased. Q4 showed stronger momentum with 26% EBITDA growth YoY. The company added 20 centres since its December 2024 IPO, reaching 68 diagnostic centres. Mature centres (>2 years) continue delivering stable 36-37% EBITDA margins. Strategic initiatives include acquiring 63% stake in Fetomat Wellness (fertility/pregnancy care) and launching a genomics vertical for genetic testing. Management guides for margin improvement as newer centres scale up.
Revenue growth is strong at 23%, but margin compression and higher finance costs are pressuring profitability. The stock may see mixed reaction—top-line momentum is positive, but investors will watch whether the company can achieve its guided margin improvement as newer centres mature.